{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:29:37Z","timestamp":1792416577394,"version":"4.4.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.lfs.2024.122823","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T22:41:00Z","timestamp":1718145660000},"page":"122823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia"],"prefix":"10.1016","volume":"351","author":[{"given":"Rita Ngozi","family":"Aguchem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent Uzochukwu","family":"Okagu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekezie Matthew","family":"Okorigwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude Obiorah","family":"Uzoechina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Chukwubuikem","family":"Nnemolisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Prince Chidike","family":"Ezeorba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.122823_bb0005","first-page":"1","article-title":"Immune mechanisms of plaque instability","volume":"8","author":"Gerhardt","year":"2022"},{"key":"10.1016\/j.lfs.2024.122823_bb0010","first-page":"1","article-title":"Dysfunctional vascular endothelium as a driver of atherosclerosis: emerging insights into pathogenesis and treatment","volume":"12","author":"Botts","year":"2021"},{"key":"10.1016\/j.lfs.2024.122823_bb0015","series-title":"The Role of Wnt Signalling in Development of Coronary Artery Disease and Its Risk Factors","author":"Liu","year":"2020"},{"key":"10.1016\/j.lfs.2024.122823_bb0020","series-title":"Inflammatory Cells in Atherosclerosis","author":"Mehu","year":"2022"},{"key":"10.1016\/j.lfs.2024.122823_bb0025","doi-asserted-by":"crossref","unstructured":"A.N. Wengrofsky, P., Lee, j., and Makaryus, Dyslipidemia and its role in the pathogenesis of atherosclerotic cardiovascular disease: implications for evaluation and targets for treatment of dyslipidemia based on recent guidelines, In Dyslipidmia NtechOpen. (2019) 32.","DOI":"10.5772\/intechopen.85772"},{"key":"10.1016\/j.lfs.2024.122823_bb0030","series-title":"Pathophysiology of Atherosclerotic Plaque Development-Contemporary Experience and New Directions in Research","author":"Kowara","year":"2021"},{"key":"10.1016\/j.lfs.2024.122823_bb0035","series-title":"Pathophysiology of Atherosclerosis","first-page":"1","author":"Jebari-benslaiman","year":"2022"},{"key":"10.1016\/j.lfs.2024.122823_bb0040","article-title":"Biomedicine & pharmacotherapy roles and mechanisms of puerarin on cardiovascular disease: a review","volume":"147","author":"Jiang","year":"2022"},{"key":"10.1016\/j.lfs.2024.122823_bb0045","first-page":"759","article-title":"New trends in dyslipidemia treatment","volume":"85","author":"Jang","year":"2021"},{"key":"10.1016\/j.lfs.2024.122823_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-021-10429-0","article-title":"Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017","volume":"21","author":"Amini","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.lfs.2024.122823_bb0055","doi-asserted-by":"crossref","unstructured":"E. Punch, J. Klein, P. Diaba-, Effects of PCSK9 Targeting: Alleviating, (2022) 1\u201315. doi:https:\/\/doi.org\/10.1161\/JAHA.121.023328.","DOI":"10.1161\/JAHA.121.023328"},{"key":"10.1016\/j.lfs.2024.122823_bb0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2020.07.019","article-title":"Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting","volume":"159","author":"Soppert","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2024.122823_bb0065","doi-asserted-by":"crossref","unstructured":"F. Qayyum, B.K. Lauridsen, R. Frikke-schmidt, K.F. Kofoed, B.G. Nordestgaard, A. Tybj\u00e6rg-hansen, Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease, (2018) 2106\u20132116. doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehy068.","DOI":"10.1093\/eurheartj\/ehy068"},{"key":"10.1016\/j.lfs.2024.122823_bb0070","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.drudis.2021.03.016","article-title":"Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: an update","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2024.122823_bb0075","series-title":"Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?","author":"Nicholls","year":"2019"},{"key":"10.1016\/j.lfs.2024.122823_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cofs.2018.02.013","article-title":"CYP7A1-rs3808607: a single nucleotide polymorphism associated with cholesterol response to functional foods","volume":"20","author":"She","year":"2018","journal-title":"Curr. Opin. Food Sci."},{"key":"10.1016\/j.lfs.2024.122823_bb0085","doi-asserted-by":"crossref","unstructured":"L. Trapani, M. Segatto, V. Pallottini, Regulation and deregulation of cholesterol homeostasis: the liver as a metabolic \u201cpower station,\u201d World J. Hepatol. 4 (2012) 184. doi:https:\/\/doi.org\/10.4254\/WJH.V4.I6.184.","DOI":"10.4254\/wjh.v4.i6.184"},{"key":"10.1016\/j.lfs.2024.122823_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2021.108878","article-title":"Regulation of cholesterol biosynthesis and lipid metabolism: a microRNA management perspective","volume":"173","author":"Bhattarai","year":"2021","journal-title":"Steroids"},{"key":"10.1016\/j.lfs.2024.122823_bb0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacc.2018.10.072","article-title":"Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week","volume":"73","author":"Armitage","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2024.122823_bb0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1755-5922.2010.00142.x","article-title":"Anacetrapib: hope for CETP inhibitors?","volume":"29","author":"Gurfinkel","year":"2011","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.lfs.2024.122823_bb0105","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0022-2275(20)36957-1","article-title":"Plasma cholesteryl ester transfer protein","volume":"34","author":"Tall","year":"1993","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0110","first-page":"291","article-title":"Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia","volume":"4","author":"Inazu","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2024.122823_bb0115","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.ATV.17.3.560","article-title":"Heterogeneity at the CETP gene locus","volume":"17","author":"Kuivenhoven","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lfs.2024.122823_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.31033\/ijrasb.9.1.2","article-title":"Assessment of cholesteryl ester transfer protein gene Taq1B polymorphism and its relationship with lipid levels of hypertensive Iraqi patients","volume":"9","author":"Al-Obaedi","year":"2022","journal-title":"Int. J. Res. Appl. Sci. Biotechnol."},{"key":"10.1016\/j.lfs.2024.122823_bb0125","doi-asserted-by":"crossref","unstructured":"K.R. Marotti, C.K. Castle, T.P. Boyle, A.H. Lin, R.W. Murray, G.W. Melchior, Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein, Nat. 1993 3646432. 364 (1993) 73\u201375. doi:https:\/\/doi.org\/10.1038\/364073a0.","DOI":"10.1038\/364073a0"},{"key":"10.1016\/j.lfs.2024.122823_bb0130","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1194\/jlr.R400007-JLR200","article-title":"A review of CETP and its relation to atherosclerosis","volume":"45","author":"De Grooth","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0135","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI118255","article-title":"Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene","volume":"96","author":"Hayek","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2024.122823_bb0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2021.3728","article-title":"Long-term benefits and harms associated with genetic cholesteryl Ester transfer protein deficiency in the general population","volume":"7","author":"Nordestgaard","year":"2022","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.lfs.2024.122823_bb0145","doi-asserted-by":"crossref","unstructured":"G.D. Arikan, S. \u0130Sbir, S.G. Yilmaz, T. \u0130Sbir, Characteristics of coronary artery disease patients who have a polymorphism in the cholesterol ester transfer protein (CETP) gene, In Vivo (Brooklyn). 33 (2019) 787\u2013792. doi:10.21873\/INVIVO.11540.","DOI":"10.21873\/invivo.11540"},{"key":"10.1016\/j.lfs.2024.122823_bb0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0021-9150(94)90073-6","article-title":"Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition","volume":"110","author":"Gaynor","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lfs.2024.122823_bb0155","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.chemosphere.2017.07.056","article-title":"Exposure to polycyclic aromatic hydrocarbons and central obesity enhanced risk for diabetes among individuals with poor lung function","volume":"185","author":"Hou","year":"2017","journal-title":"Chemosphere"},{"key":"10.1016\/j.lfs.2024.122823_bb0160","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","article-title":"Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits","volume":"273","author":"Sugano","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.122823_bb0165","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lfs.2024.122823_bb0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0021-9150(96)05981-3","article-title":"Inhibition of cholesterol ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters","volume":"128","author":"Kothari","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lfs.2024.122823_bb0175","doi-asserted-by":"crossref","unstructured":"H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, H. Shinkai, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits, Nat. 2000 4066792. 406 (2000) 203\u2013207. doi:https:\/\/doi.org\/10.1038\/35018119.","DOI":"10.1038\/35018119"},{"key":"10.1016\/j.lfs.2024.122823_bb0180","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/cs1030587","article-title":"Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia","volume":"103","author":"Huang","year":"2002","journal-title":"Clin. Sci."},{"key":"10.1016\/j.lfs.2024.122823_bb0185","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/eurheartj\/ehab889","article-title":"CETP inhibitors revisited","volume":"43","author":"Laufs","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2024.122823_bb0190","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1194\/jlr.R082735","article-title":"Cholesteryl ester transfer protein and its inhibitors","volume":"59","author":"Shrestha","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0195","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0200","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lfs.2024.122823_bb0205","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0210","doi-asserted-by":"crossref","first-page":"10E","DOI":"10.1016\/j.amjcard.2009.09.014","article-title":"Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial","volume":"104","author":"Barter","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.lfs.2024.122823_bb0215","doi-asserted-by":"crossref","first-page":"32E","DOI":"10.1016\/j.amjcard.2009.09.017","article-title":"The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors","volume":"104","author":"Vergeer","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.lfs.2024.122823_bb0220","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122823_bb0225","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2024.122823_bb0230","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial","volume":"33","author":"L\u00fcscher","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2024.122823_bb0235","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib","volume":"8","author":"Tardif","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.lfs.2024.122823_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2020.01.007","article-title":"Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib","volume":"222","author":"Tardif","year":"2020","journal-title":"Am. Heart J."},{"key":"10.1016\/j.lfs.2024.122823_bb0245","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/ATVBAHA.121.317181","article-title":"Pharmacological inhibition of CETP (cholestery ester transfer protein) increases HDL (high-density lipoprotein) that contains ApoC3 and other HDL subspecies associated with higher risk of coronary heart disease","volume":"42","author":"Furtado","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lfs.2024.122823_bb0250","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0255","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2017.04.008","article-title":"Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trial","volume":"261","author":"Nicholls","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lfs.2024.122823_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14779072.2020.1745633","article-title":"The mystery of evacetrapib - why are CETP inhibitors failing?","volume":"18","author":"Nicholls","year":"2020","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.lfs.2024.122823_bb0265","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0270","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2024.122823_bb0275","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1074248414529621","article-title":"Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with Anacetrapib in the DEFINE study","volume":"19","author":"Gotto","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2024.122823_bb0280","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2024.122823_bb0285","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","article-title":"Obicetrapib: reversing the tide of CETP inhibitor disappointments","volume":"26","author":"Kastelein","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"issue":"28","key":"10.1016\/j.lfs.2024.122823_bb0290","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"288","author":"Nicholls","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0295","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","article-title":"Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?","volume":"118","author":"Nurmohamed","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0300","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2024.122823_bb0305","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3122\/jabfm.2018.04.170447","article-title":"Hyperlipidemia: management with proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors","volume":"31","author":"Shahreyar","year":"2018","journal-title":"J. Am. Board Fam. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0310","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0315","doi-asserted-by":"crossref","unstructured":"M. Abifadel, M. Varret, J.P. Rab\u00e8s, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, A. Derr\u00e9, L. Vill\u00e9ger, M. Farnier, I. Beucler, E. Bruckert, J. Chambaz, B. Chanu, J.M. Lecerf, G. Luc, P. Moulin, J. Weissenbach, A. Prat, M. Krempf, C. Junien, N.G. Seidah, C. Boileau, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet. 2003 342. 34 (2003) 154\u2013156. doi:https:\/\/doi.org\/10.1038\/ng1161.","DOI":"10.1038\/ng1161"},{"key":"10.1016\/j.lfs.2024.122823_bb0320","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0325","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00125-016-4178-y","article-title":"PCSK9 inhibition: the dawn of a new age in cholesterol lowering?","volume":"60","author":"Preiss","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2024.122823_bb0330","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0335","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0345","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2024.122823_bb0350","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvac025","article-title":"The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis","author":"Dangas","year":"2022","journal-title":"Eur. Hear. J. - Cardiovasc. Pharmacother."},{"key":"10.1016\/j.lfs.2024.122823_bb0355","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0360","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2024.122823_bb0365","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.lfs.2024.122823_bb0370","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2024.122823_bb0375","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2024.122823_bb0380","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacl.2023.04.010","article-title":"The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia","volume":"17","author":"Luo","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.lfs.2024.122823_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020323","article-title":"Inclisiran\u2014safety and effectiveness of small interfering RNA in inhibition of PCSK-9","volume":"15","author":"Wo\u0142owiec","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2024.122823_bb0390","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2024.122823_bb0395","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lfs.2024.122823_bb0400","first-page":"1","article-title":"A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates","volume":"81","author":"Fowler","year":"2023","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.lfs.2024.122823_bb0405","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00228-021-03149-2","article-title":"A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9","volume":"77","author":"Zeitlinger","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122823_bb0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ehjcvp\/pvx010","article-title":"Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting","volume":"4","author":"Korman","year":"2018","journal-title":"Eur. Hear. Journal. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.lfs.2024.122823_bb0415","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2024.122823_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108815","article-title":"Heart failure subtypes: pathophysiology and definitions","volume":"175","author":"Swedberg","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.lfs.2024.122823_bb0425","article-title":"PCSK9 inhibitors and their use in advanced heart failure and heart transplant recipients","volume":"4","author":"Agdamag","year":"2020","journal-title":"Vessel Plus."},{"key":"10.1016\/j.lfs.2024.122823_bb0430","doi-asserted-by":"crossref","unstructured":"R.A. Beltran, K.J. Zemeir, C.R. Kimberling, M.S. Kneer, M.D. Mifflin, T.L. Broderick, Is a PCSK9 inhibitor right for your patient? A review of treatment data for individualized therapy, Int. J. Environ. Res. Public Heal. 2022, Vol. 19, Page 16899. 19 (2022) 16899. doi:https:\/\/doi.org\/10.3390\/IJERPH192416899.","DOI":"10.3390\/ijerph192416899"},{"key":"10.1016\/j.lfs.2024.122823_bb0435","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/eurheartj\/ehab431","article-title":"PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction","volume":"42","author":"Da Dalt","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2024.122823_bb0440","article-title":"PCSK-9 inhibitors and cardiovascular outcomes: a systematic review with meta-analysis","volume":"15","author":"Bodapati","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.lfs.2024.122823_bb0445","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/molecules27061983","article-title":"A recent ten-year perspective: bile acid metabolism and signaling","volume":"27","author":"Shulpekova","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2024.122823_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154120","article-title":"Alisol B 23-acetate adjusts bile acid metabolisim via hepatic FXR-BSEP signaling activation to alleviate atherosclerosis","volume":"101","author":"Fu","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.lfs.2024.122823_bb0455","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/BST20210658","article-title":"Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders","volume":"50","author":"Molinaro","year":"2022","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.lfs.2024.122823_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.lfs.2024.122823_bb0465","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.livres.2020.05.001","article-title":"Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis","volume":"4","author":"Chiang","year":"2020","journal-title":"Liver Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0470","first-page":"1.09","article-title":"Role of fibroblast growth factor 9 in bile acid homeostasis","volume":"60","author":"Seitz","year":"2022","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/j.lfs.2024.122823_bb0475","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1867","article-title":"Redundant functions of ERK1 and ERK2 maintain mouse liver homeostasis through down-regulation of bile acid synthesis","volume":"6","author":"Cingolani","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.lfs.2024.122823_bb0480","doi-asserted-by":"crossref","first-page":"37582","DOI":"10.1074\/jbc.M204909200","article-title":"Membrane-protein interactions contribute to efficient 27-hydroxylation of cholesterol by mitochondrial cytochrome P450 27A1","volume":"277","author":"Murtazina","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.122823_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21217829","article-title":"A villin-driven Fxr transgene modulates enterohepatic bile acid homeostasis and response to an n-6-enriched high-fat diet","volume":"21","author":"Wren","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122823_bb0490","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/jsfa.10115","article-title":"Regulation mechanism of silkworm pupa oil PUFAs on cholesterol metabolism in hepatic cell L-02","volume":"100","author":"Luo","year":"2020","journal-title":"J. Sci. Food Agric."},{"key":"10.1016\/j.lfs.2024.122823_bb0495","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbalip.2018.04.005","article-title":"Cholesterol and bile acid-mediated regulation of autophagy in fatty liver diseases and atherosclerosis","volume":"1863","author":"Wang","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.lfs.2024.122823_bb0500","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nutres.2019.03.003","article-title":"Eicosapentaenoic acid and docosahexaenoic acid, but not \u03b1-linolenic acid, decreased low-density lipoprotein cholesterol synergistically with estrogen via regulation of cholesterol synthesis and clearance in ovariectomized rats","volume":"66","author":"Park","year":"2019","journal-title":"Nutr. Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0505","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.2c00007","article-title":"Bile acid sequestrants for hypercholesterolemia treatment using sustainable biopolymers: recent advances and future perspectives","author":"Islam","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2024.122823_bb0510","first-page":"205","article-title":"Use and indications of cholestyramine and bile acid sequestrants, Intern","volume":"8","author":"Scaldaferri","year":"2013","journal-title":"Emerg Med"},{"key":"10.1016\/j.lfs.2024.122823_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154063","article-title":"Recent advances in nuclear receptors-mediated health benefits of blueberry","volume":"100","author":"Zou","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.lfs.2024.122823_bb0520","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3390\/ijms23031793","article-title":"Long-term dietary taurine lowers plasma levels of cholesterol and bile acids","volume":"23","author":"Tagawa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.lfs.2024.122823_bb0525","first-page":"1","article-title":"l-Arabinose improves hypercholesterolemia via regulating bile acid metabolism in high-fat-high-sucrose diet-fed mice","volume":"191","author":"Wang","year":"2022","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.lfs.2024.122823_bb0530","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1001\/archinte.158.20.2225","article-title":"Herbal medicine for the treatment of cardiovascular disease: clinical considerations","volume":"158","author":"Mashour","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0535","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fphar.2020.00422","article-title":"Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and safety","volume":"11","author":"Shaito","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122823_bb0540","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14786410903417378","article-title":"Cardiovascular friendly natural products: a promising approach in the management of CVD","volume":"24","author":"Shukla","year":"2010","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0545","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02210-15","article-title":"Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota","volume":"7","author":"Chen","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.lfs.2024.122823_bb0550","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejphar.2019.05.019","article-title":"Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor \u03b1-mediated pathway in L02\u00a0cells","volume":"855","author":"Jing","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122823_bb0555","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/mnfr.201100440","article-title":"Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism","volume":"55","author":"Shin","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0560","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/mnfr.201400366","article-title":"Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells","volume":"58","author":"Tai","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0565","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ctim.2014.07.006","article-title":"Lipid-modifying effects of adjunctive therapy with curcuminoids\u2013piperine combination in patients with metabolic syndrome: results of a randomized controlled trial","volume":"22","author":"Panahi","year":"2014","journal-title":"Complement. Ther. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0570","first-page":"22","article-title":"Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals","volume":"82","author":"Ferguson","year":"2018","journal-title":"A randomised controlled trial, Metabolism."},{"key":"10.1016\/j.lfs.2024.122823_bb0575","unstructured":"A. Javandoost, A. Afshari, M. Saberi-Karimian, A. Sahebkar, H. Safarian, M. Moammeri, B. Fathi Dizaji, S. Tavalaei, G.A. Ferns, A. Pasdar, S. Mohammad Reza Parizadeh, M. Ghayour-Mobarhan, F.B. Dizaji, The effects of curcumin and a modified curcumin formulation on serum Cholesteryl Ester Transfer Protein concentrations in patients with metabolic syndrome: a randomized, placebo-controlled clinical trial, Avicenna J. Phytomedicine. 8 (2018) 330. \/pmc\/articles\/PMC6204148\/ (accessed April 23, 2024)."},{"key":"10.1016\/j.lfs.2024.122823_bb0580","first-page":"331","article-title":"Enhancing the bioavailability and bioactivity of curcumin for disease prevention and treatment, Antioxidants","volume":"13","author":"Bertoncini-Silva","year":"2024"},{"key":"10.1016\/j.lfs.2024.122823_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031445","article-title":"Bioactive peptides: synthesis, sources, applications, and proposed mechanisms of action","volume":"23","author":"Akbarian","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122823_bb0590","doi-asserted-by":"crossref","unstructured":"C. Lammi, C. Bollati, D. Lecca, M.P. Abbracchio, A. Arnoldi, Lupin peptide T9 (GQEQSHQDEGVIVR) modulates the mutant PCSK9D374Y pathway: in vitro characterization of its dual hypocholesterolemic behavior, Nutr. 2019, Vol. 11, Page 1665. 11 (2019) 1665. doi:https:\/\/doi.org\/10.3390\/NU11071665.","DOI":"10.3390\/nu11071665"},{"key":"10.1016\/j.lfs.2024.122823_bb0595","first-page":"193","article-title":"Impact of soy \u03b2-conglycinin peptides on PCSK9 protein expression in HepG2 cells","volume":"14","author":"Macchi","year":"2022"},{"key":"10.1016\/j.lfs.2024.122823_bb0600","first-page":"1","article-title":"Techniques for extraction and isolation of natural products: a comprehensive review","author":"Zhang","year":"2018","journal-title":"Chin. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12906-023-03862-8","article-title":"In vitro antioxidant, anti-inflammatory, and anticancer activities of mixture Thai medicinal plants","volume":"23","author":"Jongrungraungchok","year":"2023","journal-title":"BMC Complement. Med. Ther."},{"key":"10.1016\/j.lfs.2024.122823_bb0610","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/molecules24030493","article-title":"The cholesterol-modulating effect of methanol extract of pigeon pea (cajanus cajan (l.) millsp.) leaves on regulating ldlr and pcsk9 expression in HepG2 cells","volume":"24","author":"Chang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2024.122823_bb0615","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1021\/acs.jafc.1c02532","article-title":"Apple polyphenol extract improves high-fat diet-induced hepatic steatosis by regulating bile acid synthesis and gut microbiota in C57BL\/6 male mice","volume":"69","author":"Li","year":"2021","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.lfs.2024.122823_bb0620","article-title":"Exploring carbohydrates for therapeutics: a review on future directions","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122823_bb0625","first-page":"186","article-title":"Carbohydrates in therapeutics, Cardiovasc. Hematol. Agents","volume":"5","author":"Kilcoyne","year":"2007","journal-title":"Med. Chem."},{"key":"10.1016\/j.lfs.2024.122823_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104631","article-title":"Geniposide reduces cholesterol accumulation and increases its excretion by regulating the FXR-mediated liver-gut crosstalk of bile acids","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0635","doi-asserted-by":"crossref","unstructured":"M.P. Adorni, F. Zimetti, M.G. Lupo, M. Ruscica, N. Ferri, Naturally occurring PCSK9 inhibitors, Nutr. 2020, Vol. 12, Page 1440. 12 (2020) 1440. doi:https:\/\/doi.org\/10.3390\/NU12051440.","DOI":"10.3390\/nu12051440"},{"key":"10.1016\/j.lfs.2024.122823_bb0640","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jff.2017.05.029","article-title":"Food matrix interaction and bioavailability of bioactive peptides: two faces of the same coin?","volume":"35","author":"Udenigwe","year":"2017","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.lfs.2024.122823_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2019.103680","article-title":"Considering food matrix and gastrointestinal effects in enhancing bioactive peptide absorption and bioavailability","volume":"64","author":"Sun","year":"2020","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.lfs.2024.122823_bb0650","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cofs.2021.03.005","article-title":"Bioaccessibility of bioactive peptides: recent advances and perspectives","volume":"39","author":"Udenigwe","year":"2021","journal-title":"Curr. Opin. Food Sci."},{"key":"10.1016\/j.lfs.2024.122823_bb0655","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2011.07.023","article-title":"Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein","volume":"219","author":"Duwensee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lfs.2024.122823_bb0660","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201600173","article-title":"Three new ergot alkaloids from the fruiting bodies of Xylaria nigripes (Kl.) sacc","volume":"14","author":"Hu","year":"2017","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.lfs.2024.122823_bb0665","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/jmf.2009.1389","article-title":"Turmeric and laurel aqueous extracts exhibit in vitro anti-atherosclerotic activity and in vivo hypolipidemic effects in a zebrafish model","volume":"14","author":"Jin","year":"2011","journal-title":"J. Med. Food"},{"key":"10.1016\/j.lfs.2024.122823_bb0670","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12272-011-0505-5","article-title":"The conformation and CETP inhibitory activity of [10]-dehydrogingerdione isolated from Zingiber officinale","volume":"34","author":"Choi","year":"2011","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0675","first-page":"172","article-title":"In vivo effects of CETP inhibitory peptides in hypercholesterolemic rabbit and cholesteryl ester transfer protein-transgenic mice","volume":"35","author":"Cho","year":"2002","journal-title":"J. Biochem. Mol. Biol."},{"key":"10.1016\/j.lfs.2024.122823_bb0680","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/molecules23051080","article-title":"Blood pressure lowering effect of cuban policosanol is accompanied by improvement of hepatic inflammation, lipoprotein profile, and HDL quality in spontaneously hypertensive rats","volume":"23","author":"Cho","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2024.122823_bb0685","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4809525","article-title":"Consumption of Cuban policosanol improves blood pressure and lipid profile via enhancement of HDL functionality in healthy women subjects: randomized, double-blinded, and placebo-controlled study","volume":"2018","author":"Cho","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2024.122823_bb0690","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8496409","article-title":"Cuban sugar cane wax acid and policosanol showed similar atheroprotective effects with inhibition of LDL oxidation and cholesteryl ester transfer via enhancement of high-density lipoproteins functionality","volume":"2019","author":"Cho","year":"2019","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.lfs.2024.122823_bb0695","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3892\/ijmm.2012.1045","article-title":"Grape skin and loquat leaf extracts and acai puree have potent anti-atherosclerotic and anti-diabetic activity in vitro and in vivo in hypercholesterolemic zebrafish","volume":"30","author":"Kim","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0700","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jnutbio.2017.04.011","article-title":"Xanthohumol, a hop-derived prenylated flavonoid, promotes macrophage reverse cholesterol transport","volume":"47","author":"Hirata","year":"2017","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.lfs.2024.122823_bb0705","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12010-018-2776-5","article-title":"New insight on a combination of policosanol and 10-dehydrogingerdione phytochemicals as inhibitors for platelet activation biomarkers and atherogenicity risk in dyslipidemic rabbits: role of CETP and PCSK9 inhibition","volume":"186","author":"Elseweidy","year":"2018","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.lfs.2024.122823_bb0710","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1074\/jbc.M114.597229","article-title":"Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1\u03b1 protein expression through the ubiquitin-proteasome degradation pathway","volume":"290","author":"Dong","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.122823_bb0715","article-title":"Ginkgolide B mediated alleviation of inflammatory cascades and altered lipid metabolism in HUVECs via targeting PCSK-9 expression and functionality","volume":"2019","author":"Wang","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2024.122823_bb0720","first-page":"394","article-title":"Potential role of lycopene in targeting proprotein convertase subtilisin\/kexin type-9 to combat hypercholesterolemia, Free Radic","volume":"108","author":"Sultan Alvi","year":"2017","journal-title":"Biol. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0725","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.biopha.2017.11.116","article-title":"Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity","volume":"96","author":"Alvi","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2024.122823_bb0730","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.numecd.2020.08.012","article-title":"Diallyl disulfide improves lipid metabolism by inhibiting PCSK9 expression and increasing LDL uptake via PI3K\/Akt-SREBP2 pathway in HepG2 cells","volume":"31","author":"Wu","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.lfs.2024.122823_bb0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-015-0325-x","article-title":"Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"15","author":"Wang","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.lfs.2024.122823_bb0740","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1074248418775377","article-title":"Inhibition of aortic calcification by policosanol in dyslipidemic rabbits is enhanced by pentoxifylline: potential role of PCSK9","volume":"23","author":"Elseweidy","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2024.122823_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153688","article-title":"Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression","volume":"91","author":"Wang","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.lfs.2024.122823_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2021.113005","article-title":"Dammarane-type saponins with proprotein convertase subtilisin\/kexin type 9 inhibitory activity from Gynostemma pentaphyllum","volume":"194","author":"Huang","year":"2022","journal-title":"Phytochemistry"},{"key":"10.1016\/j.lfs.2024.122823_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104847","article-title":"Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor","volume":"158","author":"Abdelwahed","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0760","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yexcr.2018.03.013","article-title":"Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells","volume":"366","author":"Yang","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0765","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jnutbio.2015.07.009","article-title":"Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression","volume":"26","author":"Yang","year":"2015","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.lfs.2024.122823_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114265","article-title":"Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2","volume":"278","author":"Chae","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.lfs.2024.122823_bb0775","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/jmf.2017.4069","article-title":"Black raspberry extract enhances LDL uptake in HepG2 cells by suppressing PCSK9 expression to upregulate LDLR expression","volume":"21","author":"Song","year":"2018","journal-title":"J. Med. Food"},{"key":"10.1016\/j.lfs.2024.122823_bb0780","doi-asserted-by":"crossref","first-page":"15870","DOI":"10.1074\/jbc.RA120.015623","article-title":"Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin\/kexin 9 expression","volume":"295","author":"Wang","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2024.122823_bb0785","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41401-020-0392-8","article-title":"Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin\/kexin type 9 in hyperlipidemic rats","volume":"41","author":"Su","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2024.122823_bb0790","first-page":"7105","article-title":"Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells., Saudi","volume":"28","author":"Jack","year":"2021","journal-title":"Aust. J. Biol. Sci."},{"key":"10.1016\/j.lfs.2024.122823_bb0795","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41401-019-0274-0","article-title":"23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9","volume":"41","author":"Li","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.lfs.2024.122823_bb0800","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.3390\/molecules26165094","article-title":"Acanthaster planci inhibits pcsk9 and lowers cholesterol levels in rats","volume":"26","author":"Kamaruddin","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2024.122823_bb0805","first-page":"1","article-title":"The cholesterol-lowering effect of Capsella bursa-pastoris is mediated via SREBP2 and HNF-1\u03b1-regulated PCSK9 inhibition in obese mice and HepG2 cells","volume":"10","author":"Hwang","year":"2021","journal-title":"Foods (Basel, Switzerland)."},{"key":"10.1016\/j.lfs.2024.122823_bb0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom11030463","article-title":"Dilignans with a chromanol motif discovered by molecular networking from the stem barks of magnolia obovata and their proprotein convertase subtilisin\/kexin type 9 expression inhibitory activity","volume":"11","author":"Ahn","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.lfs.2024.122823_bb0815","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1021\/acs.jafc.1c01813","article-title":"Flavonoids from whole-grain oat alleviated high-fat diet-induced hyperlipidemia via regulating bile acid metabolism and gut microbiota in mice","volume":"69","author":"Duan","year":"2021","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.lfs.2024.122823_bb0820","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1017\/S0007114513002717","article-title":"Effects of dietary plant meal and soya-saponin supplementation on intestinal and hepatic lipid droplet accumulation and lipoprotein and sterol metabolism in Atlantic salmon (Salmo salar L.)","volume":"111","author":"Gu","year":"2014","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.lfs.2024.122823_bb0825","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8827955","article-title":"Effects of rhein on bile acid homeostasis in rats","volume":"2020","author":"Xian","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2024.122823_bb0830","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4919153","article-title":"Chlorogenic acid inhibits lipid deposition by regulating the enterohepatic FXR-FGF15 pathway","volume":"2022","author":"Ye","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2024.122823_bb0835","series-title":"Mathematical Models for Cholesterol Metabolism and Transport, Process","first-page":"155","volume":"Vol. 10","author":"Zhang","year":"2022"},{"key":"10.1016\/j.lfs.2024.122823_bb0840","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.7150\/ijbs.42965","article-title":"Pleiotropic use of statins as non-lipid-lowering drugs","volume":"16","author":"Zhang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.lfs.2024.122823_bb0845","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-020-00884-2","article-title":"The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia","volume":"22","author":"Pang","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.lfs.2024.122823_bb0850","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2024.122823_bb0855","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152207","article-title":"Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the Small Intestine","volume":"11","author":"Nakano","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2024.122823_bb0860","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","article-title":"Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport","volume":"73","author":"Jia","year":"2011","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.lfs.2024.122823_bb0865","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-022-01012-y","article-title":"The Role of High-Density Lipoprotein Cholesterol in 2022","volume":"24","author":"Sirtori","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.lfs.2024.122823_bb0870","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fphys.2015.00061","article-title":"The pathophysiology of intestinal lipoprotein production","volume":"6","author":"Giammanco","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2024.122823_bb0875","first-page":"166","article-title":"The Role of Lipids and Lipoproteins in Atherosclerosis","volume":"111","author":"Linton","year":"2019","journal-title":"Science (80-. )"},{"issue":"7","key":"10.1016\/j.lfs.2024.122823_bb0880","first-page":"1","article-title":"Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics","volume":"71","author":"Duan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2024.122823_bb0885","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/nutrit\/nuy032","article-title":"Progress and perspectives in plant sterol and plant stanol research","volume":"76","author":"Jones","year":"2018","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.lfs.2024.122823_bb0890","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.plipres.2019.02.003","article-title":"Plant-based sterols and stanols in health & disease: \u201cConsequences of human development in a plant-based environment?","volume":"74","author":"Plat","year":"2019","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0895","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2024.122823_bb0900","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fcvm.2019.00069","article-title":"Effects of Exercise to Improve Cardiovascular Health","volume":"6","author":"Pinckard","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.lfs.2024.122823_bb0905","article-title":"Molecular Pathways Underlying Cholesterol Homeostasis","volume":"10","author":"Silva Afonso","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.lfs.2024.122823_bb0910","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25703-3","article-title":"Cholesteryl Ester Transfer Protein (CETP) as a Drug Target for Cardiovascular Disease","volume":"12","author":"Schmidt","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524004132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524004132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T11:05:50Z","timestamp":1725879950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524004132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":182,"alternative-id":["S0024320524004132"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122823","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"122823"}}